Last reviewed · How we verify

NCT00649233

Single-Dose Food In Vivo Bioequivalence Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets (100/50 mg; Mylan) to Lopressor HCT® Tablets (100/50 mg; Novartis) in Healthy Volunteers

Completed Phase 1 Last updated 22 April 2024
What this trial tests

Phase 1 trial testing Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg in Healthy in 32 participants. Completed in 1 February 2003.

Timeline
1 January 2003
Primary endpoint
1 February 2003
1 February 2003

Quick facts

Lead sponsorMylan Pharmaceuticals Inc
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposeother
Enrollment32
Start date1 January 2003
Primary completion1 February 2003
Estimated completion1 February 2003
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mylan Pharmaceuticals Inc — full company profile →

Who can join

18 and older, any sex, with Healthy. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The objective of this study was to investigate the bioequivalence of Mylan metoprolol tartrate/hydrochlorothiazide 100/50 mg tablets to Novartis Lopressor HCT® 100/50 mg tablets following a single, oral 100/50 mg (1 x 100/50 mg) dose administration under fed conditions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Mylan Pharmaceuticals Inc trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00649233.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing